{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T04:43:58Z","timestamp":1683089038332},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[1990,5,1]],"date-time":"1990-05-01T00:00:00Z","timestamp":641520000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[1990,5,1]],"date-time":"1990-05-01T00:00:00Z","timestamp":641520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[1990,5]]},"DOI":"10.1007\/bf00177264","type":"journal-article","created":{"date-parts":[[2004,8,22]],"date-time":"2004-08-22T08:15:28Z","timestamp":1093162528000},"page":"215-219","source":"Crossref","is-referenced-by-count":1,"title":["Ifosfamide and mesna in combination with other cytostatic drugs in the treatment of patients with advanced cancer"],"prefix":"10.1007","volume":"8","author":[{"given":"Geoffrey","family":"Falkson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin R.","family":"Chasen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hendr\u00e8 C.","family":"Falkson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF00177264_CR1","first-page":"39","volume-title":"Advances in Medical Oncology. Research and Education","author":"N Brock","year":"1979","unstructured":"Brock N: The special position of ifosfamide in the series of cytostatically active oxazaphosphorines. In: Fox BW (ed) Advances in Medical Oncology. Research and Education. Pergamon Press, Oxford and New York, 1979, pp 39\u201347"},{"key":"BF00177264_CR2","first-page":"921","volume":"32","author":"JJ Van Dyk","year":"1972","unstructured":"Van Dyk JJ, Falkson HC, Van der Merwe AM, Falkson G: Unexpected toxicity in patients treated with iphosphamide. Cancer Res 32: 921\u2013924, 1972","journal-title":"Cancer Res"},{"key":"BF00177264_CR3","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/BF00265383","volume":"19","author":"G Falkson","year":"1982","unstructured":"Falkson G, Van Dyk JJ, Stapelberg R, Falkson HC: Mesnum as a protector against kidney and bladder toxicity with high-dose ifosfamide treatment. Cancer Chemother Pharmaco19: 81\u201384, 1982","journal-title":"Cancer Chemother Pharmaco"},{"key":"BF00177264_CR4","doi-asserted-by":"crossref","unstructured":"Falkson CI, Falkson HC, Falkson G: Ifosfamide and Mesna in the treatment of malignant disease. Mesna as urothelial protector. In press: Invest New Drugs, 1989","DOI":"10.1007\/BF00170871"},{"key":"BF00177264_CR5","first-page":"14","volume":"9","author":"A Goldin","year":"1982","unstructured":"Goldin A: Ifosfamide in experimental tumor systems. Semin Oncol 9: 14\u201323, 1982","journal-title":"Semin Oncol"},{"key":"BF00177264_CR6","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/1097-0142(19840915)54:1+<1155::AID-CNCR2820541311>3.0.CO;2-E","volume":"54","author":"A Goldin","year":"1984","unstructured":"Goldin A: Dosing and sequencing for antineoplastic synergism. Cancer 54: 155\u20131160, 1984","journal-title":"Cancer"},{"key":"BF00177264_CR7","doi-asserted-by":"crossref","unstructured":"Fichtner I, Nowak CH: Pharmacological and toxicological effects of ifosfamide (holoxan) combined with mesna (uromitexan) in different murine tumor models. In: Brade, Nagel, Seeber (eds) Contr Oncol Basel, Karger 1987, 26: pp 93\u2013104","DOI":"10.1159\/000429528"},{"key":"BF00177264_CR8","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1007\/BF01740591","volume":"63","author":"JH Hartlapp","year":"1985","unstructured":"Hartlapp JH, Illiger HJ, Wolter H: Alternatives to CYVADIC combination therapy of soft-tissue sarcoma. Klin Wochenschr 63: 1160\u20131162, 1985","journal-title":"Klin Wochenschr"},{"key":"BF00177264_CR9","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1200\/JCO.1987.5.8.1191","volume":"5","author":"JS Miser","year":"1987","unstructured":"Miser JS, Kinsella TJ, Triche TJ, Tsokos M, Jarosinski P, Forquer R, Wesley R, Magrath I: Ifosfamide with mesna uroprotection and etoposide: An effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol 5: 1191\u20131198, 1987","journal-title":"J Clin Oncol"},{"key":"BF00177264_CR10","first-page":"19","volume":"16","author":"LH Einhorn","year":"1989","unstructured":"Einhorn LH: Ifosfamide in small cell lung cancer. Semin Oncol 16: 19\u201321 1989","journal-title":"Semin Oncol"},{"key":"BF00177264_CR11","first-page":"49","volume":"1","author":"HMJ Cantwell","year":"1988","unstructured":"Cantwell HMJ, Carmichael J, Ghani S, Harris AL: A phase II study of ifosfamide\/mesna with doxorubicin for adult soft tissue sarcoma. Cancer Chemother Pharmacol 1: 49\u201352, 1988","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF00177264_CR12","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1007\/BF00647439","volume":"18","author":"E Wiltshaw","year":"1986","unstructured":"Wiltshaw E, Westburg G, Harmer C, McKinna A, Fisher C: Ifosfamide plus mesna with and without adriamycin in soft tissue sarcoma. Cancer Chemother Pharmacol 18: S10-S12, 1986","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF00177264_CR13","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey D, Horton J, Davis TE, McFadden ET, Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649\u2013655, 1982","journal-title":"Am J Clin Oncol"},{"key":"BF00177264_CR14","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1093\/jnci\/80.8.556","volume":"80","author":"M Zalupski","year":"1988","unstructured":"Zalupski M, Baker LH: Ifosfamide. J Natl Cancer Inst 80: 556\u2013566, 1988","journal-title":"J Natl Cancer Inst"},{"key":"BF00177264_CR15","first-page":"955","volume":"60","author":"G Falkson","year":"1976","unstructured":"Falkson G, Falkson HC: Further experience with Isophosphamide. Cancer Treat Rep 60: 955\u2013957, 1976","journal-title":"Cancer Treat Rep"},{"key":"BF00177264_CR16","first-page":"163","volume":"63","author":"R Yazigi","year":"1984","unstructured":"Yazigi R, Wild R, Madrid J, Arraztoa J: Ifosfamide treatment of advanced ovarian cancer. Obstet Gynecol 63: 163\u2013166, 1984","journal-title":"Obstet Gynecol"},{"key":"BF00177264_CR17","unstructured":"Slater AJ, Green JA: Phase II Study of Cisplatin and Ifosfamide in the Treatment of Advanced Ovarian Carcinoma presented at the 13th International Cancer Congress, Seattle, 1982"},{"key":"BF00177264_CR18","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1200\/JCO.1986.4.1.28","volume":"4","author":"BM Wheeler","year":"1986","unstructured":"Wheeler BM, Loehrer PJ, Williams SD, Einhorn LH: Ifosfamide in refractory male germ cell tumors. J Clin Oncol 4: 28\u201334, 1986","journal-title":"J Clin Oncol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00177264.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/BF00177264\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00177264","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00177264.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:17:20Z","timestamp":1678558640000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/BF00177264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1990,5]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1990,5]]}},"alternative-id":["BF00177264"],"URL":"https:\/\/doi.org\/10.1007\/bf00177264","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[1990,5]]}}}